The promise of tumor-infiltrating lymphocytes (TIL) therapy is expanding beyond melanoma to a wide range of solid tumors, but the path to clinical success remains complex. Variability in tumor tissue ...
Exploration of the new classification of hormone receptor-positive breast cancer: Based on the genomic landscape of 2111 early to mid-stage Asian patients. Long-term outcomes in triple-negative breast ...
Tumor-infiltrating lymphocytes (TILs) are immune cells that naturally recognize and penetrate tumors to kill cancer cells, making them a promising approach for treating solid tumors. This potential ...
In a new study, TILs significantly predicted both distant disease-free survival and overall survival in early ERBB2-positive breast cancer. TIL levels ≥20% were associated with better outcomes when ...
Analysis of CA9 and PSMA expression in clear cell renal cell carcinoma (ccRCC) and the effect of prior therapies. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium.
Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...
Hosted on MSN
Reactivity to tumor antigens is important for tumor-infiltrating lymphocyte therapy, study shows
A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...
Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...
Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results